BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2013

View Archived Issues

Final results presented for glioblastoma multiforme trial of Cotara

Read More

Results from ongoing VAL-083 brain cancer trial

Read More

DS-5272 as a novel Hdm2 inhibitor for the treatment of relapsed and/or refractory MM

Read More

Otlertuzumab combined with rituximab shows promise in lymphocytic leukemia

Read More

Avanir releases results from phase II PRIME study

Read More

Ono and Receptos expand collaboration with GPCR technology platform transfer

Read More

Myriad Genetics forms research collaboration with Janssen Research & Development

Read More

Johnson & Johnson collaborates with Canadian early-stage drug technology centers

Read More

KU Leuven and Biocartis to develop diagnostic test for MMR-deficient cancer

Read More

CytRx reports data from global phase IIb trial of aldoxorubicin

Read More

Ario Pharma founded to develop therapies for respiratory indications

Read More

Novel fusion protein provides hope for hemophilia sufferers

Read More

to-BBB and Sihuan Pharmaceutical collaborate on treatments for CNS diseases

Read More

Abstral launched in Japan

Read More

MER-TIK, a novel tyrosine-protein kinase Mer inhibitor demonstrating antileukemic activity

Read More

C4 Imaging receives FDA 510(k) clearance for Sirius

Read More

E.U. funding for iHIVARNA program of HIV therapeutic vaccine

Read More

Bayer Schering Pharma patents novel sGC activators for cardiovascular disorders

Read More

Researchers at Bayer Schering Pharma present novel Mnk1 inhibitors

Read More

Venantius discloses new agents for IBD

Read More

Novel compounds for influenza prepared by European researchers

Read More

Ono Pharmaceutical synthesizes novel coagulation factor XIa inhibitors

Read More

Agents for HCV infection disclosed by Janssen R&D Ireland

Read More

Roche and Prothena collaborate on antibodies for Parkinson's disease

Read More

FDA committee recommends approval of metreleptin for generalized lipodystrophy

Read More

AstraZeneca presents novel FGFR-4 inhibitor with promising activity against HCC

Read More

Medivir begins phase IIa study combining simeprevir, TMC-647055 and JNJ-56914845

Read More

Agios Pharmaceuticals extends cancer metabolism collaboration with Celgene

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing